Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

44.74 +3.70 (+9.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Avidity Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Nasdaq Jumps Over 150 Points; Kroger Earnings Top Estimates
Via Benzinga
Thursday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Why Oxford Industries Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Is Avidity Biosciences Stock Down 20% Pre-market Today?
Via Stocktwits
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium
Via Stocktwits
Discover the top movers in Thursday's pre-market session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ... 
Via Benzinga
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Wednesday's after hours session: top gainers and losers
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Avidity Drug Shows Yearlong Gains In Duchenne Muscular Dystrophy Trial
Avidity's del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne muscular dystrophy after one year. 
Via Benzinga
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (8 Ratings)
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Analyst Expectations For Avidity Biosciences's Future
 
Via Benzinga
Avidity Biosciences (NASDAQ:RNA) Exhibits High-Quality Technical Breakout Setup
Avidity Biosciences (RNA) stock shows a strong technical breakout setup with high momentum, trading above key moving averages in a bullish trend. 
Via Chartmill
Avidity (RNA) Q2 Revenue Jumps 88%
Via The Motley Fool
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
The company is focused on treatments for forms of muscular dystrophy. 
Via Investor's Business Daily
Veritex Holdings, Sequans Communications, Canaan And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Expert Outlook: Avidity Biosciences Through The Eyes Of 11 Analysts
 
Via Benzinga
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts
 
Via Benzinga
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
Avidity shares early del-brax FSHD data showing improved mobility, strength, and safety; Phase 3 FORWARD trial now underway. 
Via Benzinga
12 Analysts Assess Avidity Biosciences: What You Need To Know
 
Via Benzinga
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock
 
Via Benzinga
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences
 
Via Benzinga
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025
Avidity's del-zota met key Phase 1/2 trial goals in DMD44, shows strong exon skipping, dystrophin restoration and creatine kinase reduction. 
Via Benzinga
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.